This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Iskedjian, M. Articles by Gehshan, A. Search for Related Content PubMed PubMed Citation Articles by Iskedjian, M. Articles by Gehshan, A. Social Bookmarking                   What's this?

Economic evaluation of Avonex® (interferon beta-1a) in patients following a single demyelinating event

PharmIdeas Research and Consulting Inc., Oakville, Ontario, Canada, skedji{at}pharmideas.com

John H Walker

PharmIdeas Research and Consulting Inc., Oakville, Ontario, Canada, Brock University, St. Catharines, Ontario, Canada

Trevor Gray

St. Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada

Colin Vicente

PharmIdeas Research and Consulting Inc., Oakville, Ontario, Canada

Thomas R Einarson

PharmIdeas Research and Consulting Inc., Oakville, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada

Adel Gehshan

Biogen Idec Canada Inc., Mississauga, Ontario, Canada

Background: Interferon beta-1a (Avonex®)30 mg, intramuscular (i.m.), once weekly is efficacious in delaying clinically definite multiple sclerosis (CDMS) following a single demyelinating event (SDE). This study determined the cost effectiveness of Avonex® compared to current treatment in delaying the onset of CDMS. Methods: A cost-effectiveness analysis (CEA) and cost-utility analysis (CUA) were performed from Ministry of Health (MoH) and societal perspectives. For CEA, the outcome of interest was time spent in the pre-CDMS state, termed monosymptomatic life years (MLY) gained. For CUA, the outcome was quality-adjusted monosymptomatic life years (QAMLY) gained. A Markov model was developed with transitional probabilities and utilities derived from the literature. Costs were reported in 2002 Canadian dollars. Costs and outcomes were discounted at 5%. The time horizon was 12 years for the CEA, and 15 years for the CUA. All uncertainties were tested via univariate and multivariate sensitivity analyses. Results: In the CEA, the incremental cost of Avonex® per MLY gained was $53 110 and $44 789 from MoH and societal perspectives, respectively. In the CUA, the incremental cost of Avonex® per QAMLY gained was $227 586 and $189 286 from MoH and societal perspectives, respectively. Both models were sensitive to the probability of progressing to CDMS and the analytical time horizon. The CUA was sensitive to the utilities value. Conclusion: Avonex® may be considered as a reasonably cost-effective approach to treatment of patients experiencing an SDE. In addition, the overall incremental cost-effectiveness profile of Avonex® improves if treatment is initiated in pre-CDMS rather than waiting until CDMS.

Key Words: Canada • cost effectiveness • economic • interferon beta-1a • multiple sclerosis • single demyelinating event

Multiple Sclerosis, Vol. 11, No. 5, 542-551 (2005)
DOI: 10.1191/1352458505ms1211oa


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?